Is there a link between fascia and cancer? From potential mechanisms to future treatment options

Fascia, the connective tissue network enveloping muscles, organs, nerves, and vasculature, plays an important role in maintaining structural integrity, biomechanical function, and integrative physiological processes. Traditionally considered a passive support structure, fascia is increasingly discussed as an active component in cancer biology, particularly within the tumor microenvironment (TME), although many mechanistic pathways remain incompletely characterized. Experimental and clinical studies suggest that tumor-associated remodeling of the extracellular matrix (ECM) within fascial tissues can increase tissue stiffness, fibrosis, and desmoplasia, changes that may facilitate tumor progression, invasion, metastasis, and immune escape, and could contribute to resistance against conventional therapies in at least some tumor entities. Cancer-associated fibroblasts (CAFs) appear to be central mediators of these processes by producing collagen, enzymatically modifying ECM structure, and influencing mechanotransduction pathways involving transcriptional regulators such as YAP/TAZ and integrins, thereby promoting pro-malignant cellular phenotypes in model systems. Fascia also interfaces closely with immune and nervous systems, potentially influencing immune cell trafficking, neuroinflammatory signaling, and systemic stress responses via the hypothalamic pituitary adrenal axis and vagal pathways, but these interactions are only partly understood in the context of cancer. Emerging preclinical and early clinical data indicate that physical exercise and movement-based interventions, including controlled stretching and other mechanical therapies, may modulate fascial stiffness and low-grade inflammation, with possible effects on tumor biology and patient-reported outcomes that appear at least partly distinct from those of aerobic exercise, yet this requires confirmation in larger, well-controlled trials. Clinically, patterns of fascial involvement and ECM remodeling correlate with aggressive behavior and poorer outcome in several cancers, suggesting potential prognostic value, although standardized assessment and validation across entities are still lacking. Targeting fascia- and ECM-related components, such as collagen cross-linking enzymes (for example lysyl oxidase), is being explored as a translational strategy to enhance drug delivery and immunotherapy responses, but these approaches remain largely experimental. Priority areas for future research include the development of imaging and molecular tools for more precise fascia assessment, mechanobiological interventions tailored to individual patients, and rigorous clinical trials evaluating fascia-modulating therapies as adjuncts in integrative oncology. In summary, current evidence supports a view of fascia as a dynamic, multifunctional tissue that is likely implicated in cancer progression and therapy response while highlighting substantial knowledge gaps and the need for cautious, hypothesis-driven translation into clinical practice.